
|Articles|September 1, 2003
Emerging Gold Standard?
San Francisco - More than two decades after collagen launched a revolution in filling facial wrinkles, the FDA is expected to approve the soft filler hyaluronic acid (Restylane, Q-Med) within the next few months. The approval will be partly based on a phase III study that showed it provides longer-lasting correction of nasolabial folds than collagen.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















